News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: Hisun-Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK)-Simcere Pharmaceutical Group JVs Come Into Focus


5/28/2013 9:32:15 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 25, 2013 -- Zhejiang Hisun Pharma contributed 75 drug products to gain 51% control of its JV with Pfizer, while Pfizer added eight drugs; the Merck-Simcere JV is focused onsix cardiovascular drugs, two from Simcere and the rest from Merck; 3SBio’s shareholders voted to accept a go-private offer priced at $16.70 per ADS; Janssen Pharma, a division of Johnson & Johnson, has four new medical entities awaiting approval in China and expects to file an additional nine NMEs by 2017; GlaxoSmithKline cut the prices of its China drugs and watched revenues jump as a result; Zensun Sci & Tech, a Shanghai-San Diego biopharma, reported positive results from four Phase II trials of its heart failure drug, Neucardin™; the CFDA approved clinical trials of a novel AIDS treatment developed at Zhengzhou University; Curative Medical will oversee a China clinical trial for ALung’s respiratory medical device; and China’s bird flu crisis has been contained, according to UN officials. More details….

Stock Symbols: (SHA: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE: SCR) (NSDQ: SSRX) (NYSE: JNJ) (NYSE: GSK)



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES